June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Evaluation of the Effects of Cis-UCA in a Murine Model for Allergic Conjunctivitis
Author Affiliations & Notes
  • James McLaughlin
    Ora, Inc., Andover, MA
  • Andy Whitlock
    Ora, Inc., Andover, MA
  • Laura Belen
    Ora, Inc., Andover, MA
  • Jennifer Brackett
    Ora, Inc., Andover, MA
  • Burkhard Blank
    Laurantis Pharma, Turku, Finland
  • Footnotes
    Commercial Relationships James McLaughlin, Ora, Inc. (E); Andy Whitlock, Ora, Inc. (E); Laura Belen, Ora, Inc. (E); Jennifer Brackett, Ora, Inc. (E); Burkhard Blank, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2554. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      James McLaughlin, Andy Whitlock, Laura Belen, Jennifer Brackett, Burkhard Blank; Evaluation of the Effects of Cis-UCA in a Murine Model for Allergic Conjunctivitis. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2554.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The purpose of this study was to investigate the potential of topically applied Cis-urocanic acid (Cis-UCA) in reducing the signs of allergic conjunctivitis.

Methods: We used a murine model of allergic conjunctivitis based upon the allergen challenge paradigm. Animals were sensitized with subcutaneously injected short ragweed (SRW) allergen, and then challenged 18 days later with topical SRW. Following challenge mice were randomized into treatment groups (n=10) and given test compounds QID for 4 days. Challenges were repeated BID on the third and fourth days of treatment; their responses to allergen were evaluated after challenges 1 and 4. Cis-UCA was provided at concentrations of 0.0, 1.0, and 2.5%. Additional test agents included olopatadine 0.1% (Patanol®) and prednisolone (Pred) acetate 1.0% as positive controls. Cis-UCA vehicle was used as the negative control. Following challenges hyperemia, squinting, discharge or tearing, and lid swelling were evaluated using a novel Micron III imaging system. Allergic responses were graded on a 0-4 scale using the proprietary Ora clinical grading scale.

Results: For the first challenge, only the Pred reduced hyperemia significantly; animals receiving either Pred or olopatadine showed significant reduction for challenge 4. None of the scores for squinting showed a significant difference, although the Pred and the 2.5% Cis-UCA were the lowest average scores. A combined score averaged from hyperemia and squinting scores showed a clear tendency toward reduced scores for olopatadine, Pred, and Cis-UCA 2.5%, with the Pred and the Cis-UCA scores significantly different from vehicle at p values of 0.05 and 0.001 respectively.

Conclusions: Mouse models provide a useful means to screen potential drugs for clinical trials. In this study we compared the efficacy of Cis-UCA, to several drugs currently used to treat ocular allergic conjunctivitis. Olopatadine is a drug of choice for seasonal allergies, while Pred is used to treat more severe or chronic allergies. In this trial, Cis-UCA 2.5% behaved similar to the steroid comparator. Our results provide encouraging data that suggest that this new class of anti-inflammatories may be useful therapeutic for acute and chronic allergic conjunctivitis.

Keywords: 421 anterior segment • 475 conjunctivitis • 479 cornea: clinical science  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×